This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A pharmaceutical composition comprising 3 wt.% to 50 wt.% telmisartan dispersed in a dissolving matrix comprising:

(a) a basic agent, selected from NaOH, KOH, $NaHCO_3$, $KHCO_3$, Na_2CO_3, K_2CO_3, Na_2HPO_4, K_2HPO_4 or meglumine, in a molar ratio of basic agent:telmisartan of 1:1 to 10:1;

(b) about 1 wt.% to about 20 wt.% of polyoxamers having an average molecular weight of about 2000 to 12000;

(c) 25 wt.% to 70 wt.% of a water-soluble diluent; and

(d) 0 wt.% to 20 wt.% of one or more additional excipients and/or adjuvants,

wherein the sum of all components is 100%; and

wherein the pharmaceutical composition is in the form of a capsule or a tablet.

2. – 5. (Canceled)

6. (Previously presented) The pharmaceutical composition of claim 1, wherein the poloxamers comprise poloxamer 182LF, poloxamer 331, or poloxamer 188.

7. (Original) The pharmaceutical composition of claim 1, wherein the water-soluble diluent is selected from carbohydrates, oligosaccharides, and sugar alcohols.

8. (Original) The pharmaceutical composition of claim 1, wherein the water-soluble diluent is glucose, sucrose, erythritol, sorbitol, mannitol, dulcitol, ribitol, or xylitol.

9. (Original) The pharmaceutical composition of claim 1, wherein the additional excipients and/or adjuvants are selected from binders, carriers, lubricants, flow control agents, crystallization retarders, solubilizers, and coloring agents.

10. (Canceled)

11. (Currently Amended) The pharmaceutical composition of claim 1 ~~or claim 10~~, comprising a dosage unit of 10 mg to 160 mg of telmisartan.

12. (Currently Amended) The pharmaceutical composition of ~~claim 10~~ claim 1, comprising a dosage unit of 10 mg to 160 mg of telmisartan.

13. (Previously presented) A bilayer pharmaceutical tablet comprising:

(a) a first telmisartan-containing tablet layer comprising the pharmaceutical composition of one of claims 1 or 6 to 9; and

(b) a second tablet layer containing a diuretic in a disintegrating tablet matrix.

14. (Currently Amended) A process for preparing the pharmaceutical composition of claim 1 using a fluid-bed granulation process, comprising:

(i) preparing a granulation liquid as an aqueous solution by dissolving 3 wt.% to 50 wt.% of telmisartan together with the following components in water or in a mixture solution of ethanol and water:

(a) a basic agent, selected from NaOH, KOH, $NaHCO_3$, $KHCO_3$, Na_2CO_3, K_2CO_3, Na_2HPO_4, K_2HPO_4 or meglumine, in a molar ratio of basic agent:telmisartan of 1:1 to 10:1, and

(b) polyoxamers having an average molecular weight of about 2000 to 12000 in an amount of about 1 wt.% to about 20 wt.%;

(ii) placing 25 wt.% to 70 wt.% of a water-soluble diluent in a fluid-bed granulator, optionally together with 10 wt.% to 20 wt.% of a dry binder, including a premix-step;

(iii) carrying out the fluid-bed granulation using the granulation liquid for spraying on the components placed in the granulator;

(iv) drying the granulation thus obtained and, optionally, screening the granulate obtained;

(v) optionally blending the granulate with one or more additional excipients and/or adjuvants; ~~and~~

(vi) optionally milling the granulate thus obtained in order to produce a powdery composition of defined particle size distribution; and

(vii) providing the granulate in a tablet or capsule form;

wherein all percentage amounts given are related to the final composition to be prepared.

15. (Previously presented) A process for preparing the pharmaceutical composition of claim 1 using a spray drying process, comprising:

(i) preparing an aqueous spray-solution by dissolving 3 wt.% to 50 wt.% of telmisartan together with the following components in water or mixture solution of ethanol and water:

(a) a basic agent, selected from NaOH, KOH, $NaHCO_3$, $KHCO_3$, Na_2CO_3, K_2CO_3, Na_2HPO_4, K_2HPO_4 or meglumine, in a molar ratio of basic agent:telmisartan of 1:1 to 10:1, and

(b) polyoxamers having an average molecular weight of about 2000 to 12000 in an amount of about 1 wt.% to 20 wt.%;

(ii) spray-drying the aqueous spray-solution to obtain a spray-dried granulate;

(iii) mixing the spray-dried granulate with 25 wt.% to 70 wt.% of a water-soluble diluent to obtain a premix;

(iv) optionally mixing the premix with a lubricant;

(v) optionally adding additional excipients and/or adjuvants in any of steps (i) to (iv); and

(vi) providing the granulate in a tablet or capsule form;~~,~~

wherein all percentage amounts given are related to the final composition to be prepared.